The duo plan to establish a global center of excellence in theranostics, taking advantage of Siemens’ state-of-the-art technology and software to advance the use of radiopharmaceuticals in cancer care.
Is portable MRI suitable for finding abnormalities in the brains of patients receiving new amyloid-targeting therapy for Alzheimer’s disease? Clinical researchers are about to find out.
Alexander Fanaroff, MD, said the late-breaking BE ACTIVE clinical trial presented at ACC.24 offers a blueprint for how to get patients to be more physically active.